This Treatment Saved My Life

0 Views

07/09/23

Robyn was diagnosed with Diffuse Large B-Cell Lymphoma. Four years after going through R-CHOP chemotherapy, she relapsed and went through more chemotherapy, a stem cell transplant, and radiation. She relapsed a second time only 9 months after therapy. This time, she joined a clinical trial for CAR T-cell therapy.

In this conversation, Robyn, a three-time DLBCL survivor, and two top lymphoma specialists, Dr. Tycel Phillips from the City of Hope and Dr. Joshua Brody from Mount Sinai, discuss the latest research and treatment options n the most common subtype of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL).

Thank you to Genmab and AbbVie for their support of our patient education program.

Full story & transcript → https://www.thepatientstory.co....m/medical-experts/dl

Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story

02:06 - What is diffused large B-cell lymphoma.
03:54 - What are the different treatment options for DLBCL?
05:45 - What is the treatment for a patient who relapses in the first 6-12 months?
09:25 - What is CAR T-Cell Therapy?
11:54 - Benefits and challenges of CAR T-Cell Therapy.
13:46 - CAR T-Cell therapy for refractory patients

#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch